Results 71 to 80 of about 1,866 (169)

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The majority of bimekizumab‐treated patients shifted from severe to mild and moderate IHS4 stages, and nearly 25% achieved an IHS4 of 0 by Week 48. Bimekizumab led to clinically meaningful improvements across IHS4 outcome measures. These data highlight an opportunity to address the need for effective treatments against draining tunnels.
Thrasyvoulos Tzellos, Evangelos J. Giamarellos‐Bourboulis, Kelsey R. van Straalen, Antonio Martorell, Brian Kirby, Afsaneh Alavi, Koremasa Hayama, Saakshi Khattri, Wayne Gulliver, Christopher J. Sayed, Leah Davis, Robert L. Rolleri, Christina Crater, Ingrid Pansar, Jérémy Lambert, Christos C. Zouboulis   +15 more
wiley   +1 more source

Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial

, 2023
BACKGROUND: BE SURE 1-year results demonstrated the superior efficacy of bimekizumab compared with adalimumab with no unexpected safety findings.
Diamant Thaçi, Veerle Vanvoorden, Cynthia Madden, de Cuyper, D., Vanvoorden, V., Menno A de Rie, Curdin Conrad, Dirk de Cuyper, Strober, B., Vender, R., Kimball, A.B., Bruce Strober, Maggie Wang, Wang, M., de Rie, M.A., Madden, C., Conrad, C., David M Pariser, Thaçi, D., Pariser, D.M., Ron Vender, Alexa B Kimball   +21 more
core   +1 more source

Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden

, 2023
Aims: To evaluate the cost-effectiveness of bimekizumab, an inhibitor of IL-17F and IL-17A, against biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARD) for psoriatic arthritis (PsA) from the Swedish healthcare system perspective.
Oldsberg, Linnea, Oldsberg, Linnea,, Willems, Damon, Willems, Damon,, Valgerdur Sigurdardottir, Engstrom, Anna,, Tor Olofsson, Berling, Patric, Melis, Lode, Sigurdardottir, Valgerdur, Devian Parra, Linnea Oldsberg, Patric Berling, Melis, Lode,, Sigurdardottir, Valgerdur,, Anna Engstrom, Olofsson, Tor, Sadler, Susannah,, Lode Melis, Engstrom, Anna, Parra-Padilla, Devian,, Parra-Padilla, Devian, Berling, Patric,, Olofsson, Tor,, Damon Willems, Susannah Sadler, Sadler, Susannah, Lund University.   +27 more
core   +1 more source

Real-Life Effectiveness and Safety of Bimekizumab in Plaque Psoriasis Involving Difficult-to-Treat Areas: A 52-Week, Retrospective Real-World, Single-Center Study

Journal of Clinical Medicine
Background: Psoriasis is a chronic inflammatory disease that frequently affects difficult-to-treat areas such as the scalp, nails, genitalia, and palms/soles, with significant physical and psychological burden.
M. Bianco, F. D'Oria, Gioele Ghezzi, L. Ibba, S. Di Giulio, M. Valenti, A. Costanzo, A. Narcisi, L. Gargiulo   +8 more
semanticscholar   +1 more source

Measuring success in HS treatment from the physician's and the patient's perspective

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Integrated clinician (HiSCR, IHS4, IHS4‐55, HS‐IGA) and patient (HiSQOL, DLQI) scores, combined with imaging‐based fibrosis and inflammation assessment, redefine treatment success in hidradenitis suppurativa by aligning treat‐to‐target strategies with both inflammatory control and irreversible structural damage.
Georgios Nikolakis, Monika Arenbergerova, Zeljko Mijuskovic, Baoxi Wang, Christos C. Zouboulis   +4 more
wiley   +1 more source

Bimekizumab for treating moderate to severe chronic plaque psoriasis: A NICE Technology Appraisal

, 2021
This report is a critique of the company’s submission to the NICE Fast Track Appraisal programme of a cost comparison of bimekizumab for treating moderate to severe plaque ...
Lord, Joanne, Scott, David Alexander, Hazell, Lorna, Kalita, Neelam, Shepherd, Jonathan   +4 more
core   +1 more source

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab

Frontiers in Pharmacology
BackgroundBimekizumab, a humanized monoclonal antibody, exerts its therapeutic effect by inhibiting interleukin-17A/F and is indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients.
Zhuomiao Lin, Xihui Yu, Meiqing Yang, Jialan Xu, Jiahong Zhong   +4 more
doaj   +1 more source

Optimizing surgery in hidradenitis suppurativa

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Surgery in hidradenitis suppurativa should be matched to disease extent. A structured six‐step approach—comprehensive assessment, optimal timing, ultrasound‐guided mapping, tailored intervention, individualized reconstruction and structured wound care—integrated with targeted systemic therapy optimizes outcomes and reduces recurrence.
Eva Vilarrasa, Philippe Guillem, Barbara Horváth, Marco Romanelli, Carolin E.Frost, Falk G. Bechara, Øystein Grimstad, Antonio Martorell   +7 more
wiley   +1 more source

Real-World Effectiveness of Bimekizumab in Predominantly Difficult-to-Treat Patients with Psoriatic Arthritis Followed in a Combined Dermatology–Rheumatology Clinic: A 24-Week Multicenter Study

Rheumatology and Therapy
Bimekizumab (BKZ), a monoclonal antibody targeting interleukin (IL)-17A and IL-17F, has shown high efficacy in clinical trials. However, real-world data on its use in psoriatic arthritis (PsA) are limited.
A. Zabotti, N. Cabas, M. De Martino, L. Idolazzi, A. Guiotto, F. Bellinato, I. Giovannini, Beatrice Gabrielli, P. Gisondi, E. Errichetti, Maurizio Rossini, G. Stinco, L. Quartuccio   +12 more
semanticscholar   +1 more source

Successful bimekizumab retreatment after secondary failure in multi‐biologic‐resistant psoriasis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nicole Kah Mun Yoong, Melinda Withington, Francis Yi Xing Lai, Paul Curnow, Senhong Lee   +4 more
wiley   +1 more source